Digital videos can be a vital source of cancer health education
While no viable pharmacological agents or drugs have been able to target Bfl-1 to date, a few have emerged to target only Mcl-1.
Pellecchia is optimistic the research project will present several innovative drug discovery approaches that are necessary to tackle challenging drug targets such as Mcl-1 and Bfl-1.
"Our studies suggest that Bfl-1 antagonists and/or dual action Mcl-1/Bfl-1 antagonists would hold great promise for novel apoptosis-based therapies in melanoma, lung cancer, and potentially other tumors," he said. "Therapeutic options for chemotherapy resistant cancers are limited. Our studies aim at addressing this critical unmet medical need."
Pellecchia's team will focus on deriving novel, potent, and irreversible agents that target Bfl-1, and other agents that simultaneously target both Bfl-1 and Mcl-1.
"These are challenging goals, but our preliminary data give us hope and confidence that we may succeed due, in part, to innovative drug targeting approaches we have employed," he said.
John Jefferson Perry, an assistant professor of biochemistry and co-investigator, will receive a portion of the funds to perform crystallography studies on the most promising agents derived by the research team.
"We are excited to use protein crystallography analyses to help study these novel antagonists," Perry said. "Knowledge of the antagonists' interaction with the target can be immensely helpful in these cancer-focused structure-based drug design studies."
The project will support two project scientists and two graduate students. Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology